Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 8/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 6/20 | 0.34 |
| ▸ | PRMT8 | Q9NR22 | 3/20 | 0.34 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | XPO1 | O14980 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19432338 | 0.87 | PRMT1 (0.37) | PRMT1PRMT6PRMT8PRMT3CARM1 | |
| SCHEMBL19904792 | 0.87 | PRMT1 (0.45) | PRMT1PRMT6PRMT8PRMT3CARM1 | |
| SCHEMBL19432089 | 0.85 | TMEM97 (0.37) | PRMT1TMEM97SIGMAR1 | |
| SCHEMBL16128991 | 0.81 | PRMT1 (0.38) | PRMT1PRMT6PRMT8PRMT3CARM1 | |
| SCHEMBL16124062 | 0.81 | PRMT1 (0.38) | PRMT1PRMT6PRMT8PRMT3CARM1 | |
| SCHEMBL16124057 | 0.79 | PRMT1 (0.37) | PRMT1PRMT6PRMT8PRMT3CARM1 | |
| SCHEMBL16129019 | 0.79 | PRMT1 (0.43) | PRMT1PRMT6PRMT8PRMT3CARM1 | |
| SCHEMBL16128999 | 0.79 | PDE3B (0.36) | PRMT1PRMT6PRMT8PRMT3CARM1 | |
| SCHEMBL16129014 | 0.79 | PRMT1 (0.38) | PRMT1PRMT6PRMT8PRMT3CARM1 | |
| SCHEMBL16128993 | 0.79 | PRMT1 (0.57) | PRMT1PRMT6PRMT8PRMT3CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190077795-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077795-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | PRMT1 1/4885PRMT6 4/4885PRMT8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.